In previously published pre-clinical models of cancerous lesions, NPS technology has been shown to induce immunogenic cell death (ICD), a process that leads to the exposure of the unique cancer cell antigens to the immune system, resulting in the generation of cytotoxic T cells and the mounting of an adaptive immune response targeted against those cells. Based on this foundation of pre-clinical evidence, we believe NPS technology has the potential to play a role in immuno-oncology. Applications in immuno-oncology are a longer-term potential opportunity and we continue to evaluate NPS technology and our CellFX System in clinical and pre-clinical studies.

Basal Cell Carcinoma